Kiromic BioPharma, Inc. (KRBP)
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors.
The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L.
The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019.
Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
|IPO Date||Oct 16, 2020|
|CEO||Pietro Bersani CPA, J.D.|
7707 Fannin St., Suite 140
Houston, Texas 77054
|Fiscal Year||January - December|
|Pietro Bersani CPA, J.D.||Chief Executive Officer and Director|
|Dr. Scott Dahlbeck M.D., Pharm.D., PharmD||Chief of Staff|
|Daniel Clark||Chief Financial Officer|
|Dr. Leonardo Mirandola Ph.D.||Chief Scientific Officer|
|Dr. Michael Ryan Ph.D.||Chief Bioinformatics Research Computing Officer|
Latest SEC Filings
|Nov 20, 2023||25-NSE||Filing|
|Nov 14, 2023||10-Q||Quarterly Report|
|Nov 9, 2023||8-K||Current Report|
|Nov 6, 2023||8-K||Current Report|
|Oct 3, 2023||8-K||Current Report|
|Oct 2, 2023||8-K||Current Report|
|Sep 26, 2023||8-K||Current Report|
|Sep 13, 2023||8-K||Current Report|
|Aug 29, 2023||8-K||Current Report|
|Aug 15, 2023||S-8||Securities to be offered to employees in employee benefit plans|